Correction: Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study.

PLoS ONE. 2017;12(2):e0172184 DOI 10.1371/journal.pone.0172184


Journal Homepage

Journal Title: PLoS ONE

ISSN: 1932-6203 (Online)

Publisher: Public Library of Science (PLoS)

LCC Subject Category: Medicine | Science

Country of publisher: United States

Language of fulltext: English

Full-text formats available: PDF, HTML, XML



Jesús Troya
Pablo Ryan
Esteban Ribera
Daniel Podzamczer
Victor Hontañón
Jose Alberto Terrón
Vicente Boix
Santiago Moreno
Pilar Barrufet
Manuel Castaño
Ana Carrero
María José Galindo
Ignacio Suárez-Lozano
Hernando Knobel
Miguel Raffo
Javier Solís
María Yllescas
Herminia Esteban
Juan González-García
Juan Berenguer
Arkaitz Imaz


Peer review

Editorial Board

Instructions for authors

Time From Submission to Publication: 24 weeks


Abstract | Full Text

[This corrects the article DOI: 10.1371/journal.pone.0164455.].